Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimer…
Biotechnology
US, South San Francisco [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Allogene Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2020 | - | -2.122 | - | 2 | - | -264 | - | -257 | - | -273 | - | 636 |
| 2021 | - | -1.964 | - | 38 | - | -275 | - | -264 | - | -274 | - | 8,312 |
| 2022 | - | -2.368 | - | 0.18 | - | -300 | - | -287 | - | -298 | - | 38 |
| 2023 | - | -2.009 | - | 0.13 | - | -327 | - | -281 | - | -293 | - | 29 |
| 2024 | -2.0900 | -1.332 | 0.10 | 0.02 | -327 | -212 | -300 | 0.00 | -570 | 0.00 | 71 | 5 |
| 2025 | - | -1.354 | - | 0.03 | - | -210 | - | 0.01 | - | 0.01 | - | 5 |
| 2026 | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F61/td> | - | 2.F61 | - | 2.F61 |
| 2027 | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F71/td> | - | 1.F71 | - | 1.F71 |
| 2028 | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F81/td> | - | 0.F81 | - | 0.F81 |